<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03741530</url>
  </required_header>
  <id_info>
    <org_study_id>KY20182067-X-3</org_study_id>
    <nct_id>NCT03741530</nct_id>
  </id_info>
  <brief_title>Glibenclamide Advantage in Treating Edema After Intracerebral Hemorrhage</brief_title>
  <acronym>GATE-ICH</acronym>
  <official_title>Glibenclamide Advantage in Treating Edema After Intracerebral Hemorrhage (GATE-ICH): a Multi-center Randomized, Controlled, Assessor-blinded Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xijing Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xijing Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the present study is to explore the efficacy of small doses of oral&#xD;
      glibenclamide on brain edema after acute primary intracerebral hemorrhage (ICH), and&#xD;
      improving the prognosis of patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In order to explore the efficacy and safety of oral glibenclamide on brain edema after acute&#xD;
      primary ICH, a web-based 1:1 randomization process will be employed to assign 220 subjects to&#xD;
      Glibenclamide group (giving standard management for ICH plus glibenclamide) or Control group&#xD;
      (giving standard management for ICH). The investigators will make a neurofunctional&#xD;
      assessment at baseline, and 3 days, 7 days, 90 days after enrollment. The investigators also&#xD;
      assess the midline shift, and the change in the volume of ICH and perihematomal edema (PHE)&#xD;
      from the initial to follow-up (3 days and 7days after enrollment). The serious adverse events&#xD;
      of all-cause mortality, cardiac-related and blood glucose-related adverse events will be&#xD;
      collected to assess the safety of glibenclamide.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 25, 2018</start_date>
  <completion_date type="Actual">September 23, 2020</completion_date>
  <primary_completion_date type="Actual">September 23, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of death or major disability</measure>
    <time_frame>90 days after the onset</time_frame>
    <description>Unfavourable outcome including death and disability is defined as patients achieving modified Rankin Scale (mRS) ≥3. The mRS is used for measuring the degree of disability or dependence in the daily activities of patients with stroke or other neurological diseases. The total score of the scale runs from 0 (perfect health without symptoms) to 6 (death).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change in the midline shift from the initial to follow-up CT scans</measure>
    <time_frame>3 days after onset</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in the volume of ICH from the initial to follow-up CT scans</measure>
    <time_frame>3 days after onset</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in the volume of PHE from the initial to follow-up CT scans</measure>
    <time_frame>3 days after onset</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in the volume of ICH from the initial to follow-up CT scans</measure>
    <time_frame>7 days after onset</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in the volume of PHE from the initial to follow-up CT scans</measure>
    <time_frame>7 days after onset</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of death or major disability</measure>
    <time_frame>3 days after onset</time_frame>
    <description>Unfavourable outcome including death and disability is defined as patients achieving modified Rankin Scale (mRS) ≥3. The mRS is used for measuring the degree of disability or dependence in the daily activities of patients with stroke or other neurological diseases. The total score of the scale runs from 0 (perfect health without symptoms) to 6 (death).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>National Institute of Health stroke scale</measure>
    <time_frame>3 days after onset</time_frame>
    <description>The National Institutes of Health Stroke Scale (NIHSS) is used by healthcare providers to evaluate the impairment caused by stroke. The total score of the scale runs from 0 to 42. The higher score is an indicative of more severe impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glasgow Coma Scale</measure>
    <time_frame>3 days after onset</time_frame>
    <description>The Glasgow Coma Scale is a scale for measuring the conscious state of patients with neurological diseases. The total score of the scale runs from 3 (deep coma or death) to 15 (fully awake person).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Barthel Index</measure>
    <time_frame>3 days after onset</time_frame>
    <description>The Barthel Index scale is used to measure performance in activities of daily living (ADL). The total score of the scale runs from 0 to 100. The high score of the scale represents favourable performance in activities of daily life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of death or major disability</measure>
    <time_frame>7 days after onset</time_frame>
    <description>Unfavourable outcome including death and disability is defined as patients achieving modified Rankin Scale (mRS) ≥3. The mRS is used for measuring the degree of disability or dependence in the daily activities of patients with stroke or other neurological diseases. The total score of the scale runs from 0 (perfect health without symptoms) to 6 (death).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>National Institute of Health stroke scale</measure>
    <time_frame>7 days after onset</time_frame>
    <description>The National Institutes of Health Stroke Scale (NIHSS) is used by healthcare providers to evaluate the impairment caused by stroke. The total score of the scale runs from 0 to 42. The higher score is an indicative of more severe impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glasgow Coma Scale</measure>
    <time_frame>7 days after onset</time_frame>
    <description>The Glasgow Coma Scale is a scale for measuring the conscious state of patients with neurological diseases. The total score of the scale runs from 3 (deep coma or death) to 15 (fully awake person).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Barthel Index</measure>
    <time_frame>7 days after onset</time_frame>
    <description>The Barthel Index scale is used to measure performance in activities of daily living (ADL). The total score of the scale runs from 0 to 100. The high score of the scale represents favourable performance in activities of daily life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Barthel Index</measure>
    <time_frame>90 days after onset</time_frame>
    <description>The Barthel Index scale is used to measure performance in activities of daily living (ADL). The total score of the scale runs from 0 to 100. The high score of the scale represents favourable performance in activities of daily life.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of hypoglycemia</measure>
    <time_frame>7 days after admission</time_frame>
    <description>Blood glucose &lt;3.1 mmol/L</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of symptomatic hypoglycemia</measure>
    <time_frame>7 days after admission</time_frame>
    <description>Blood glucose &lt;3.1 mmol/L with investigator-identified hypoglycemic symptoms</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of cardiac-related Adverse Events and Serious Adverse Events</measure>
    <time_frame>7 days after admission</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of all-cause mortality</measure>
    <time_frame>90 days after onset</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>During hospitalization</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">220</enrollment>
  <condition>Intracerebral Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Glibenclamide group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Giving standard management for ICH plus glibenclamide tablets, 1.25 mg 3 times daily, orally or through gastric tube, for 7 consecutive days after enrollment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Giving standard management for ICH</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glibenclamide Tablets</intervention_name>
    <description>Giving glibenclamide tablets, 1.25 mg 3 times daily, orally or through gastric tube, for 7 consecutive days after enrollment.</description>
    <arm_group_label>Glibenclamide group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard management for ICH</intervention_name>
    <description>Usual care and drug in hospital</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Glibenclamide group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18-70 years with a primary ICH&#xD;
&#xD;
          2. A baseline CT with basal ganglia hemorrhage of 5 to 30 mL&#xD;
&#xD;
          3. Glasgow Coma Scale (GCS) score ≥ 6&#xD;
&#xD;
          4. Symptom onset less than 72 hours prior to admission&#xD;
&#xD;
          5. Informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Supratentorial ICH planned to evacuation of a large hematoma&#xD;
&#xD;
          2. Hemorrhage breaking into ventricles of brain&#xD;
&#xD;
          3. Prior significant disability (mRS ≥ 3)&#xD;
&#xD;
          4. Severe renal disease (i.e., renal disorder requiring dialysis ) or eGFR&#xD;
             &lt;30ml/min/1.73m2&#xD;
&#xD;
          5. Severe liver disorder, or ALT &gt;3 times or bilirubin &gt;2 times upper limit of normal&#xD;
&#xD;
          6. Blood glucose &lt; 55 mg/dL (3.1 mmol/L）at enrollment, or with the history of&#xD;
             hypoglycemia&#xD;
&#xD;
          7. With acute ST elevation infarction, or decompensated heart failure, or cardiac arrest,&#xD;
             or acute coronary syndrome, or known history of admission for acute coronary syndrome,&#xD;
             or acute myocardial infarction, or coronary intervention in the past 3 months&#xD;
&#xD;
          8. Treatment with sulfonylurea in the past 7 days, including glyburide, glyburide plus&#xD;
             metformin, glimepiride, repaglinide, glipizide, gliclazide, tolbutamide and&#xD;
             glibornuride&#xD;
&#xD;
          9. Treatment with bosentan in the past 7 days&#xD;
&#xD;
         10. Be allergic to sulfa or other sulfonylurea drugs&#xD;
&#xD;
         11. Known G6PD deficiency&#xD;
&#xD;
         12. Pregnant women&#xD;
&#xD;
         13. Breast-feeding women disagreeing to participate the study or stop breastfeeding during&#xD;
             and after the study&#xD;
&#xD;
         14. Be enrolled in other non-observation-only study with receiving an investigational drug&#xD;
&#xD;
         15. Refusing to be enrolled, or having poor compliance, or tending to withdraw&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wen Jiang, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Department of Neurology, Xijing Hospital, Fourth Military Medical</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ankang Central Hospital</name>
      <address>
        <city>Ankang</city>
        <state>Shaanxi</state>
        <zip>725000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hanzhong Central Hospital</name>
      <address>
        <city>Hanzhong</city>
        <state>Shaanxi</state>
        <zip>723000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xijing Hospital</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tangdu Hospital</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710038</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xianyang Central Hospital</name>
      <address>
        <city>Xianyang</city>
        <state>Shaanxi</state>
        <zip>712000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Keep RF, Hua Y, Xi G. Intracerebral haemorrhage: mechanisms of injury and therapeutic targets. Lancet Neurol. 2012 Aug;11(8):720-31. doi: 10.1016/S1474-4422(12)70104-7. Epub 2012 Jun 13. Review.</citation>
    <PMID>22698888</PMID>
  </reference>
  <reference>
    <citation>Gebel JM Jr, Jauch EC, Brott TG, Khoury J, Sauerbeck L, Salisbury S, Spilker J, Tomsick TA, Duldner J, Broderick JP. Natural history of perihematomal edema in patients with hyperacute spontaneous intracerebral hemorrhage. Stroke. 2002 Nov;33(11):2631-5.</citation>
    <PMID>12411653</PMID>
  </reference>
  <reference>
    <citation>Inaji M, Tomita H, Tone O, Tamaki M, Suzuki R, Ohno K. Chronological changes of perihematomal edema of human intracerebral hematoma. Acta Neurochir Suppl. 2003;86:445-8.</citation>
    <PMID>14753483</PMID>
  </reference>
  <reference>
    <citation>Butcher KS, Baird T, MacGregor L, Desmond P, Tress B, Davis S. Perihematomal edema in primary intracerebral hemorrhage is plasma derived. Stroke. 2004 Aug;35(8):1879-85. Epub 2004 Jun 3.</citation>
    <PMID>15178826</PMID>
  </reference>
  <reference>
    <citation>Xi G, Keep RF, Hoff JT. Mechanisms of brain injury after intracerebral haemorrhage. Lancet Neurol. 2006 Jan;5(1):53-63. Review.</citation>
    <PMID>16361023</PMID>
  </reference>
  <reference>
    <citation>Shi Y, Leak RK, Keep RF, Chen J. Translational Stroke Research on Blood-Brain Barrier Damage: Challenges, Perspectives, and Goals. Transl Stroke Res. 2016 Apr;7(2):89-92. doi: 10.1007/s12975-016-0447-9. Epub 2016 Jan 13.</citation>
    <PMID>26757714</PMID>
  </reference>
  <reference>
    <citation>Jiang B, Li L, Chen Q, Tao Y, Yang L, Zhang B, Zhang JH, Feng H, Chen Z, Tang J, Zhu G. Role of Glibenclamide in Brain Injury After Intracerebral Hemorrhage. Transl Stroke Res. 2017 Apr;8(2):183-193. doi: 10.1007/s12975-016-0506-2. Epub 2016 Nov 3.</citation>
    <PMID>27807801</PMID>
  </reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>November 8, 2018</study_first_submitted>
  <study_first_submitted_qc>November 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2018</study_first_posted>
  <last_update_submitted>April 21, 2021</last_update_submitted>
  <last_update_submitted_qc>April 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Intracerebral hemorrhage</keyword>
  <keyword>Perihematomal edema</keyword>
  <keyword>Disability</keyword>
  <keyword>Clinical trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cerebral Hemorrhage</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glyburide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

